• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

August 5, 2019
Company Drug/Device Medical Condition Status
Miracor Medical SA PiCSO therapy heart attack Phase 1 trial initiated enrolling 114 subjects with anterior STEMI, TIMI 0 & 1 Flow, at nine clinical sites in Western Europe
Reflow Medical, Inc. Temporary Spur Stent System peripheral artery disease (PAD), occlusive disease affecting below-the-knee (BTK) arteries Phase 1 trial initiated
I-Mab Biopharma Tracon Pharmaceuticals, Inc. TJD5 (TJ004309) advanced solid tumors Phase 1 trial initiated
AC Immune SA ACI-35.030 Alzheimer’s disease (AD) Phase 1b/2a trial initiated
Proteostasis Therapeutics, Inc. cystic fibrosis transmembrane conductance regulator (CFTR) modulator combinations doublet (PTI-808 and PTI-801) and triplet (PTI-808, PTI-801 and PTI-428) cystic fibrosis (CF) Phase 2 trial initiated enrolling 30 F508del homozygous and 30 F508del heterozygous subjects
Arena Pharmaceuticals olorinab gastrointestinal (GI) disorders Phase 2 trial initiated enrolling 240 subjects experiencing abdominal pain associated with IBS, including IBS with constipation (IBS-C) or IBS with diarrhea (IBS-D) in sites across the U.S.
Relmada Therapeutics, Inc. REL-1017 (dextromethadone) treatment-resistant depression Phase 2 trial initiated enrolling 62 subjects
BELLUS Health Inc. BLU-5937 chronic cough Phase 2 trial initiated enrolling 65 subjects with refractory chronic cough at 12 sites in the U.S. and U.K.
Auris Medical Holding Ltd. AM-125 acute vertigo Phase 2 trial initiated enrolling 138 subjects who suffer from acute vertigo following surgical removal of a vestibular schwannoma in six European countries and Canada
Resolve Therapeutics RSLV-132 Systemic Lupus Erythematosus Phase 2a trial initiated enrolling 64 subjects at 20 sites across the U.S.
Abivax ABX464-301 moderate to severe active rheumatoid arthritis (RA) Phase 2a trial initiated enrolling 60 subjects in France, Poland, Czech Republic and Hungary
Modra Pharmaceuticals B.V. ModraDoc006/r metastatic Castration-Resistant Prostate Cancer (mCRPC) Phase 2b trial initiated enrolling 100 subjects with mCRPC eligible for first line systemic chemotherapy at 40 sites in the U.S. and Europe
Biohaven Pharmaceutical Holding Company Ltd. verdiperstat Multiple System Atrophy (MSA) Phase 3 trial initiated enrolling 250 subjects at 50 sites in the U.S. and Europe
AZTherapies, Inc. ALZT-OP1 early Alzheimer’s disease Phase 3 trial initiated enrolling 620 subjects with early stage Alzheimer’s disease, ages 55-79
Nektar Therapeutics Bristol-Myers Squibb bempegaldesleukin (NKTR-214) in combination with Opdivo (nivolumab) subjects with previously untreated unresectable or metastatic melanoma Breakthrough Therapy designation granted by the FDA
Endotronix, Inc. Cordella Pulmonary Artery (PA) Pressure Sensor System chronic heart failure IDE approval granted by the FDA
Intersect ENT PROPEL mini steroid Straight Delivery System (SDS) frontal and ethmoid sinus surgery Approval granted by the FDA
Retrophin, Inc. THIOLA EC (tiopronin) 100 mg and 300 mg tablets cystinuria Approval granted by the FDA
Merck KEYTRUDA (pembrolizumab) subjects with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (Combined Positive Score [CPS] ≥10) with disease progression after one or more prior lines of systemic therapy Approval granted by the FDA
Bayer Nubeqa (darolutamide) non-metastatic castration-resistant prostate cancer (nmCRPC) Approval granted by the FDA

 

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing